<?xml version='1.0' encoding='utf-8'?>
<document id="22356350"><sentence text="Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray."><entity charOffset="35-45" id="DDI-PubMed.22356350.s1.e0" text="azelastine" /><entity charOffset="50-72" id="DDI-PubMed.22356350.s1.e1" text="fluticasone propionate" /><pair ddi="false" e1="DDI-PubMed.22356350.s1.e0" e2="DDI-PubMed.22356350.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s1.e0" e2="DDI-PubMed.22356350.s1.e1" /></sentence><sentence text="• The topical second generation anti-histamine azelastine hydrochloride (AZE) and the potent corticosteroid fluticasone propionate (FP) are well established first-line treatments in allergic rhinitis (AR)"><entity charOffset="37-71" id="DDI-PubMed.22356350.s2.e0" text="histamine azelastine hydrochloride" /><entity charOffset="73-76" id="DDI-PubMed.22356350.s2.e1" text="AZE" /><entity charOffset="93-130" id="DDI-PubMed.22356350.s2.e2" text="corticosteroid fluticasone propionate" /><entity charOffset="132-134" id="DDI-PubMed.22356350.s2.e3" text="FP" /><pair ddi="false" e1="DDI-PubMed.22356350.s2.e0" e2="DDI-PubMed.22356350.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s2.e0" e2="DDI-PubMed.22356350.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22356350.s2.e0" e2="DDI-PubMed.22356350.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22356350.s2.e0" e2="DDI-PubMed.22356350.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22356350.s2.e1" e2="DDI-PubMed.22356350.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22356350.s2.e1" e2="DDI-PubMed.22356350.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22356350.s2.e1" e2="DDI-PubMed.22356350.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22356350.s2.e2" e2="DDI-PubMed.22356350.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22356350.s2.e2" e2="DDI-PubMed.22356350.s2.e3" /></sentence><sentence text=" • MP29-02, a novel intranasal AZE and FP formulation, has been shown to control AR symptoms faster and better than standard intranasal AZE or FP"><entity charOffset="31-32" id="DDI-PubMed.22356350.s3.e0" text="AZE" /><entity charOffset="136-137" id="DDI-PubMed.22356350.s3.e1" text="AZE" /><entity charOffset="39-40" id="DDI-PubMed.22356350.s3.e2" text="FP" /><entity charOffset="143-144" id="DDI-PubMed.22356350.s3.e3" text="FP" /><pair ddi="false" e1="DDI-PubMed.22356350.s3.e0" e2="DDI-PubMed.22356350.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s3.e0" e2="DDI-PubMed.22356350.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22356350.s3.e0" e2="DDI-PubMed.22356350.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22356350.s3.e0" e2="DDI-PubMed.22356350.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22356350.s3.e2" e2="DDI-PubMed.22356350.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22356350.s3.e2" e2="DDI-PubMed.22356350.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22356350.s3.e2" e2="DDI-PubMed.22356350.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22356350.s3.e1" e2="DDI-PubMed.22356350.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22356350.s3.e1" e2="DDI-PubMed.22356350.s3.e3" /></sentence><sentence text=" • The systemic bioavailabilities of marketed AZE and FP nasal spray products have been established at about 40% and 1% only, respectively"><entity charOffset="46-47" id="DDI-PubMed.22356350.s4.e0" text="AZE" /><entity charOffset="54-55" id="DDI-PubMed.22356350.s4.e1" text="FP" /><pair ddi="false" e1="DDI-PubMed.22356350.s4.e0" e2="DDI-PubMed.22356350.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s4.e0" e2="DDI-PubMed.22356350.s4.e1" /></sentence><sentence text=" • For new combination medicinal products such as MP29-02, the determination of possible pharmacokinetic (PK) drug-drug interactions between both active components and formulation-based bioavailability alterations is essential" /><sentence text="" /><sentence text="• This paper provides for the first time information on potential drug-drug interactions, AZE and FP bioavailability and disposition characteristics of each component administered by the novel nasal spray formulation MP29-02"><entity charOffset="90-91" id="DDI-PubMed.22356350.s7.e0" text="AZE" /><entity charOffset="98-99" id="DDI-PubMed.22356350.s7.e1" text="FP" /><pair ddi="false" e1="DDI-PubMed.22356350.s7.e0" e2="DDI-PubMed.22356350.s7.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s7.e0" e2="DDI-PubMed.22356350.s7.e1" /></sentence><sentence text=" • The studies employed highly sensitive FP and AZE LC-MS/MS assays and could therefore be conducted with recommended therapeutic doses, thereby circumventing previously recognized draw-backs that required nasal bioavailability studies to be conducted using supra-therapeutic doses"><entity charOffset="48-49" id="DDI-PubMed.22356350.s8.e0" text="AZE" /><entity charOffset="41-42" id="DDI-PubMed.22356350.s8.e1" text="FP" /><pair ddi="false" e1="DDI-PubMed.22356350.s8.e1" e2="DDI-PubMed.22356350.s8.e1" /><pair ddi="false" e1="DDI-PubMed.22356350.s8.e1" e2="DDI-PubMed.22356350.s8.e0" /></sentence><sentence text=" • No significant PK drug-drug interaction between the active components AZE and FP was noted for MP29-02"><entity charOffset="73-74" id="DDI-PubMed.22356350.s9.e0" text="AZE" /><entity charOffset="81-82" id="DDI-PubMed.22356350.s9.e1" text="FP" /><pair ddi="false" e1="DDI-PubMed.22356350.s9.e0" e2="DDI-PubMed.22356350.s9.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s9.e0" e2="DDI-PubMed.22356350.s9.e1" /></sentence><sentence text=" • AZE bioavailabilty was equivalent when MP29-02 data were compared with MP29-02-AZE-mono and Astelin®"><entity charOffset="74-90" id="DDI-PubMed.22356350.s10.e0" text="MP29-02-AZE-mono" /><entity charOffset="95-102" id="DDI-PubMed.22356350.s10.e1" text="Astelin" /><entity charOffset="3-9" id="DDI-PubMed.22356350.s10.e2" text="AZE" /><entity charOffset="82-88" id="DDI-PubMed.22356350.s10.e3" text="AZE" /><pair ddi="false" e1="DDI-PubMed.22356350.s10.e2" e2="DDI-PubMed.22356350.s10.e2" /><pair ddi="false" e1="DDI-PubMed.22356350.s10.e2" e2="DDI-PubMed.22356350.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s10.e2" e2="DDI-PubMed.22356350.s10.e3" /><pair ddi="false" e1="DDI-PubMed.22356350.s10.e2" e2="DDI-PubMed.22356350.s10.e1" /><pair ddi="false" e1="DDI-PubMed.22356350.s10.e0" e2="DDI-PubMed.22356350.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s10.e0" e2="DDI-PubMed.22356350.s10.e3" /><pair ddi="false" e1="DDI-PubMed.22356350.s10.e0" e2="DDI-PubMed.22356350.s10.e1" /><pair ddi="false" e1="DDI-PubMed.22356350.s10.e3" e2="DDI-PubMed.22356350.s10.e3" /><pair ddi="false" e1="DDI-PubMed.22356350.s10.e3" e2="DDI-PubMed.22356350.s10.e1" /></sentence><sentence text=" • Increased FP exposure was observed with MP29-02-based products compared with FP-BI"><entity charOffset="13-15" id="DDI-PubMed.22356350.s11.e0" text="FP" /><entity charOffset="80-82" id="DDI-PubMed.22356350.s11.e1" text="FP" /><pair ddi="false" e1="DDI-PubMed.22356350.s11.e0" e2="DDI-PubMed.22356350.s11.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s11.e0" e2="DDI-PubMed.22356350.s11.e1" /></sentence><sentence text=" FP serum concentrations were generally very low with all investigational products suggesting no clinically meaningful pharmacodynamic differences in terms of systemic safety"><entity charOffset="1-2" id="DDI-PubMed.22356350.s12.e0" text="FP" /></sentence><sentence text="" /><sentence text="To determine azelastine hydrochloride (AZE) and fluticasone propionate (FP) bioavailabilities of the novel nasal spray combination product MP 29-02, compared with MP29-02-based products containing only AZE (MP29-02-AZE-mono), FP (MP29-02-FP-mono), marketed AZE and FP single entity products (Astelin® and FP Boehringer-Ingelheim; FP-BI)"><entity charOffset="13-37" id="DDI-PubMed.22356350.s14.e0" text="azelastine hydrochloride" /><entity charOffset="39-42" id="DDI-PubMed.22356350.s14.e1" text="AZE" /><entity charOffset="48-70" id="DDI-PubMed.22356350.s14.e2" text="fluticasone propionate" /><entity charOffset="72-74" id="DDI-PubMed.22356350.s14.e3" text="FP" /><entity charOffset="207-223" id="DDI-PubMed.22356350.s14.e4" text="MP29-02-AZE-mono" /><entity charOffset="202-217" id="DDI-PubMed.22356350.s14.e5" text="AZE" /><entity charOffset="215-230" id="DDI-PubMed.22356350.s14.e6" text="AZE" /><entity charOffset="257-272" id="DDI-PubMed.22356350.s14.e7" text="AZE" /><entity charOffset="226-241" id="DDI-PubMed.22356350.s14.e8" text="FP" /><entity charOffset="238-253" id="DDI-PubMed.22356350.s14.e9" text="FP" /><entity charOffset="265-280" id="DDI-PubMed.22356350.s14.e10" text="FP" /><entity charOffset="305-320" id="DDI-PubMed.22356350.s14.e11" text="FP" /><entity charOffset="330-345" id="DDI-PubMed.22356350.s14.e12" text="FP" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e0" e2="DDI-PubMed.22356350.s14.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e0" e2="DDI-PubMed.22356350.s14.e1" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e0" e2="DDI-PubMed.22356350.s14.e2" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e0" e2="DDI-PubMed.22356350.s14.e3" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e0" e2="DDI-PubMed.22356350.s14.e5" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e0" e2="DDI-PubMed.22356350.s14.e4" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e0" e2="DDI-PubMed.22356350.s14.e6" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e0" e2="DDI-PubMed.22356350.s14.e8" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e0" e2="DDI-PubMed.22356350.s14.e9" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e0" e2="DDI-PubMed.22356350.s14.e7" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e0" e2="DDI-PubMed.22356350.s14.e10" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e0" e2="DDI-PubMed.22356350.s14.e11" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e0" e2="DDI-PubMed.22356350.s14.e12" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e1" e2="DDI-PubMed.22356350.s14.e1" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e1" e2="DDI-PubMed.22356350.s14.e2" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e1" e2="DDI-PubMed.22356350.s14.e3" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e1" e2="DDI-PubMed.22356350.s14.e5" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e1" e2="DDI-PubMed.22356350.s14.e4" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e1" e2="DDI-PubMed.22356350.s14.e6" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e1" e2="DDI-PubMed.22356350.s14.e8" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e1" e2="DDI-PubMed.22356350.s14.e9" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e1" e2="DDI-PubMed.22356350.s14.e7" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e1" e2="DDI-PubMed.22356350.s14.e10" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e1" e2="DDI-PubMed.22356350.s14.e11" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e1" e2="DDI-PubMed.22356350.s14.e12" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e2" e2="DDI-PubMed.22356350.s14.e2" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e2" e2="DDI-PubMed.22356350.s14.e3" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e2" e2="DDI-PubMed.22356350.s14.e5" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e2" e2="DDI-PubMed.22356350.s14.e4" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e2" e2="DDI-PubMed.22356350.s14.e6" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e2" e2="DDI-PubMed.22356350.s14.e8" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e2" e2="DDI-PubMed.22356350.s14.e9" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e2" e2="DDI-PubMed.22356350.s14.e7" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e2" e2="DDI-PubMed.22356350.s14.e10" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e2" e2="DDI-PubMed.22356350.s14.e11" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e2" e2="DDI-PubMed.22356350.s14.e12" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e3" e2="DDI-PubMed.22356350.s14.e3" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e3" e2="DDI-PubMed.22356350.s14.e5" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e3" e2="DDI-PubMed.22356350.s14.e4" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e3" e2="DDI-PubMed.22356350.s14.e6" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e3" e2="DDI-PubMed.22356350.s14.e8" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e3" e2="DDI-PubMed.22356350.s14.e9" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e3" e2="DDI-PubMed.22356350.s14.e7" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e3" e2="DDI-PubMed.22356350.s14.e10" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e3" e2="DDI-PubMed.22356350.s14.e11" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e3" e2="DDI-PubMed.22356350.s14.e12" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e5" e2="DDI-PubMed.22356350.s14.e5" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e5" e2="DDI-PubMed.22356350.s14.e4" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e5" e2="DDI-PubMed.22356350.s14.e6" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e5" e2="DDI-PubMed.22356350.s14.e8" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e5" e2="DDI-PubMed.22356350.s14.e9" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e5" e2="DDI-PubMed.22356350.s14.e7" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e5" e2="DDI-PubMed.22356350.s14.e10" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e5" e2="DDI-PubMed.22356350.s14.e11" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e5" e2="DDI-PubMed.22356350.s14.e12" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e4" e2="DDI-PubMed.22356350.s14.e4" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e4" e2="DDI-PubMed.22356350.s14.e6" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e4" e2="DDI-PubMed.22356350.s14.e8" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e4" e2="DDI-PubMed.22356350.s14.e9" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e4" e2="DDI-PubMed.22356350.s14.e7" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e4" e2="DDI-PubMed.22356350.s14.e10" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e4" e2="DDI-PubMed.22356350.s14.e11" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e4" e2="DDI-PubMed.22356350.s14.e12" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e6" e2="DDI-PubMed.22356350.s14.e6" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e6" e2="DDI-PubMed.22356350.s14.e8" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e6" e2="DDI-PubMed.22356350.s14.e9" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e6" e2="DDI-PubMed.22356350.s14.e7" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e6" e2="DDI-PubMed.22356350.s14.e10" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e6" e2="DDI-PubMed.22356350.s14.e11" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e6" e2="DDI-PubMed.22356350.s14.e12" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e8" e2="DDI-PubMed.22356350.s14.e8" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e8" e2="DDI-PubMed.22356350.s14.e9" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e8" e2="DDI-PubMed.22356350.s14.e7" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e8" e2="DDI-PubMed.22356350.s14.e10" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e8" e2="DDI-PubMed.22356350.s14.e11" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e8" e2="DDI-PubMed.22356350.s14.e12" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e9" e2="DDI-PubMed.22356350.s14.e9" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e9" e2="DDI-PubMed.22356350.s14.e7" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e9" e2="DDI-PubMed.22356350.s14.e10" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e9" e2="DDI-PubMed.22356350.s14.e11" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e9" e2="DDI-PubMed.22356350.s14.e12" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e7" e2="DDI-PubMed.22356350.s14.e7" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e7" e2="DDI-PubMed.22356350.s14.e10" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e7" e2="DDI-PubMed.22356350.s14.e11" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e7" e2="DDI-PubMed.22356350.s14.e12" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e10" e2="DDI-PubMed.22356350.s14.e10" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e10" e2="DDI-PubMed.22356350.s14.e11" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e10" e2="DDI-PubMed.22356350.s14.e12" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e11" e2="DDI-PubMed.22356350.s14.e11" /><pair ddi="false" e1="DDI-PubMed.22356350.s14.e11" e2="DDI-PubMed.22356350.s14.e12" /></sentence><sentence text="" /><sentence text="Two randomized, three period, six sequence, three treatment crossover studies were conducted in healthy subjects" /><sentence text=" Study 1 administered 200 µg FP as MP29-02, MP29-02-FP-mono or FP-BI"><entity charOffset="29-30" id="DDI-PubMed.22356350.s17.e0" text="FP" /><entity charOffset="52-53" id="DDI-PubMed.22356350.s17.e1" text="FP" /><entity charOffset="63-64" id="DDI-PubMed.22356350.s17.e2" text="FP" /><pair ddi="false" e1="DDI-PubMed.22356350.s17.e0" e2="DDI-PubMed.22356350.s17.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s17.e0" e2="DDI-PubMed.22356350.s17.e1" /><pair ddi="false" e1="DDI-PubMed.22356350.s17.e0" e2="DDI-PubMed.22356350.s17.e2" /><pair ddi="false" e1="DDI-PubMed.22356350.s17.e1" e2="DDI-PubMed.22356350.s17.e1" /><pair ddi="false" e1="DDI-PubMed.22356350.s17.e1" e2="DDI-PubMed.22356350.s17.e2" /></sentence><sentence text=" Study 2 administered 548 µg AZE as MP29-02, MP29-02-AZE-mono or Astelin®"><entity charOffset="65-72" id="DDI-PubMed.22356350.s18.e0" text="Astelin" /><entity charOffset="29-35" id="DDI-PubMed.22356350.s18.e1" text="AZE" /><entity charOffset="53-59" id="DDI-PubMed.22356350.s18.e2" text="AZE" /><pair ddi="false" e1="DDI-PubMed.22356350.s18.e1" e2="DDI-PubMed.22356350.s18.e1" /><pair ddi="false" e1="DDI-PubMed.22356350.s18.e1" e2="DDI-PubMed.22356350.s18.e2" /><pair ddi="false" e1="DDI-PubMed.22356350.s18.e1" e2="DDI-PubMed.22356350.s18.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s18.e2" e2="DDI-PubMed.22356350.s18.e2" /><pair ddi="false" e1="DDI-PubMed.22356350.s18.e2" e2="DDI-PubMed.22356350.s18.e0" /></sentence><sentence text=" Each dose consisted of two sprays/nostril" /><sentence text=" Serum FP and plasma AZE were followed over 24 (FP) and 120 h (AZE) and quantified by LC-MS/MS"><entity charOffset="21-23" id="DDI-PubMed.22356350.s20.e0" text="AZE" /><entity charOffset="63-65" id="DDI-PubMed.22356350.s20.e1" text="AZE" /><entity charOffset="7-9" id="DDI-PubMed.22356350.s20.e2" text="FP" /><entity charOffset="48-50" id="DDI-PubMed.22356350.s20.e3" text="FP" /><pair ddi="false" e1="DDI-PubMed.22356350.s20.e2" e2="DDI-PubMed.22356350.s20.e2" /><pair ddi="false" e1="DDI-PubMed.22356350.s20.e2" e2="DDI-PubMed.22356350.s20.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s20.e2" e2="DDI-PubMed.22356350.s20.e3" /><pair ddi="false" e1="DDI-PubMed.22356350.s20.e2" e2="DDI-PubMed.22356350.s20.e1" /><pair ddi="false" e1="DDI-PubMed.22356350.s20.e0" e2="DDI-PubMed.22356350.s20.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s20.e0" e2="DDI-PubMed.22356350.s20.e3" /><pair ddi="false" e1="DDI-PubMed.22356350.s20.e0" e2="DDI-PubMed.22356350.s20.e1" /><pair ddi="false" e1="DDI-PubMed.22356350.s20.e3" e2="DDI-PubMed.22356350.s20.e3" /><pair ddi="false" e1="DDI-PubMed.22356350.s20.e3" e2="DDI-PubMed.22356350.s20.e1" /></sentence><sentence text=" Peak (C(max) ) and total exposures AUC(0,t(last) ) were compared between the treatments by anova" /><sentence text="" /><sentence text="Study 1: Average FP C(max) was very low with all products (≤ 10 pg ml(-1) )"><entity charOffset="17-18" id="DDI-PubMed.22356350.s23.e0" text="FP" /></sentence><sentence text=" FP AUC(0,t(last) ) point estimates (90% CIs) for MP29-02 : MP29-02-FP-mono and MP29-02 : FP-BI ratios (%) were 93"><entity charOffset="1-2" id="DDI-PubMed.22356350.s24.e0" text="FP" /><entity charOffset="68-69" id="DDI-PubMed.22356350.s24.e1" text="FP" /><entity charOffset="90-91" id="DDI-PubMed.22356350.s24.e2" text="FP" /><pair ddi="false" e1="DDI-PubMed.22356350.s24.e0" e2="DDI-PubMed.22356350.s24.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s24.e0" e2="DDI-PubMed.22356350.s24.e1" /><pair ddi="false" e1="DDI-PubMed.22356350.s24.e0" e2="DDI-PubMed.22356350.s24.e2" /><pair ddi="false" e1="DDI-PubMed.22356350.s24.e1" e2="DDI-PubMed.22356350.s24.e1" /><pair ddi="false" e1="DDI-PubMed.22356350.s24.e1" e2="DDI-PubMed.22356350.s24.e2" /></sentence><sentence text="6 (83" /><sentence text="6, 104" /><sentence text="7) and 161" /><sentence text="1 (137" /><sentence text="1, 189" /><sentence text="3)" /><sentence text=" Corresponding ratios for C(max) were 91" /><sentence text="0 (82" /><sentence text="5, 100" /><sentence text="4) and 157" /><sentence text="4 (132" /><sentence text="5, 187" /><sentence text="1)" /><sentence text=" Study 2: AZE AUC(0,t(last) ) point estimates (90% CIs) for MP29-02 : MP29-02-AZE-mono and MP29-02 : Astelin® ratios (%) were 98"><entity charOffset="101-108" id="DDI-PubMed.22356350.s38.e0" text="Astelin" /><entity charOffset="10-16" id="DDI-PubMed.22356350.s38.e1" text="AZE" /><entity charOffset="78-84" id="DDI-PubMed.22356350.s38.e2" text="AZE" /><pair ddi="false" e1="DDI-PubMed.22356350.s38.e1" e2="DDI-PubMed.22356350.s38.e1" /><pair ddi="false" e1="DDI-PubMed.22356350.s38.e1" e2="DDI-PubMed.22356350.s38.e2" /><pair ddi="false" e1="DDI-PubMed.22356350.s38.e1" e2="DDI-PubMed.22356350.s38.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s38.e2" e2="DDI-PubMed.22356350.s38.e2" /><pair ddi="false" e1="DDI-PubMed.22356350.s38.e2" e2="DDI-PubMed.22356350.s38.e0" /></sentence><sentence text="8 (91" /><sentence text="0, 107" /><sentence text="4) and 105" /><sentence text="5 (95" /><sentence text="6, 116" /><sentence text="4)" /><sentence text=" Corresponding outcomes for C(max) were 102" /><sentence text="7 (92" /><sentence text="1, 114" /><sentence text="4) and 107" /><sentence text="3 (92" /><sentence text="6, 124" /><sentence text="3)" /><sentence text="" /><sentence text="No interactions of AZE and FP were found with the MP29-02 formulation"><entity charOffset="19-21" id="DDI-PubMed.22356350.s53.e0" text="AZE" /><entity charOffset="27-29" id="DDI-PubMed.22356350.s53.e1" text="FP" /><pair ddi="false" e1="DDI-PubMed.22356350.s53.e0" e2="DDI-PubMed.22356350.s53.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s53.e0" e2="DDI-PubMed.22356350.s53.e1" /></sentence><sentence text=" Azelastine bioavailability was similar for MP29-02 and Astelin®"><entity charOffset="1-11" id="DDI-PubMed.22356350.s54.e0" text="Azelastine" /><entity charOffset="56-63" id="DDI-PubMed.22356350.s54.e1" text="Astelin" /><pair ddi="false" e1="DDI-PubMed.22356350.s54.e0" e2="DDI-PubMed.22356350.s54.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s54.e0" e2="DDI-PubMed.22356350.s54.e1" /></sentence><sentence text=" Maximum and total FP exposure was higher for MP29-02-based products compared with FP-BI"><entity charOffset="19-25" id="DDI-PubMed.22356350.s55.e0" text="FP" /><entity charOffset="83-89" id="DDI-PubMed.22356350.s55.e1" text="FP" /><pair ddi="false" e1="DDI-PubMed.22356350.s55.e0" e2="DDI-PubMed.22356350.s55.e0" /><pair ddi="false" e1="DDI-PubMed.22356350.s55.e0" e2="DDI-PubMed.22356350.s55.e1" /></sentence><sentence text=" FP concentrations were generally very low with all investigational products and did not suggest clinically meaningful differences concerning systemic safety"><entity charOffset="1-2" id="DDI-PubMed.22356350.s56.e0" text="FP" /></sentence><sentence text="" /></document>